Danel (Adir Yeoshua) Ltd. (IL:DANE)
TASE:DANE
Top Page
Danel
(TASE:DANE)
Select Model
Select Model
Rating:61Neutral
Price Target:
46,547.00
▲(0.25% Upside)
Action:ReiteratedDate:03/26/26
The score is primarily supported by improved 2025 financial performance (profitability recovery, steady revenue growth, and better leverage), but is held back by weak technical momentum (price below key moving averages with negative MACD) and only moderate valuation support (P/E ~21 with a ~3.17% dividend yield).
Positive Factors
Steady revenue growth
Consistent top-line growth across 2020–2025 demonstrates resilient demand for Danel’s nursing and home-care services, supporting recurring service-fee revenue tied to long-term care programs. This durable revenue base improves predictability of cash flows and supports medium-term planning.
Negative Factors
Persistently meaningful leverage
Although leverage improved in 2025, historically meaningful debt levels leave the company exposed if margins weaken or funding conditions tighten. Ongoing leverage constrains flexibility and increases sensitivity to cash-flow volatility in a service business with modest margins.
Read all positive and negative factors
Positive Factors
Negative Factors
Steady revenue growth
Consistent top-line growth across 2020–2025 demonstrates resilient demand for Danel’s nursing and home-care services, supporting recurring service-fee revenue tied to long-term care programs. This durable revenue base improves predictability of cash flows and supports medium-term planning.
Read all positive factors
Danel (DANE) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪2.61B
Dividend Yield2.98%
Average Volume (3M)11.82K
Price to Earnings (P/E)23.2
Beta (1Y)0.94
Revenue Growth5.94%
EPS Growth-52.48%
CountryIL
Employees4,290
SectorConsumer Defensive
Sector Strength42
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)385.60
Shares Outstanding5,924,323
10 Day Avg. Volume13,517
30 Day Avg. Volume11,824
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)5.35
Price to Sales (P/S)0.94
P/FCF Ratio18.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Danel Business Overview & Revenue Model
Company Description
Danel (DANE) is a technology-driven company specializing in the development and deployment of innovative software solutions for the healthcare and financial sectors. The company focuses on enhancing operational efficiencies and customer engagement...
How the Company Makes Money
Danel makes money mainly by delivering care-related services and receiving service fees for providing and managing those services. A key revenue stream is nursing/home-care: the company supplies caregivers and care programs and is paid for the pro...
Danel Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
68
Positive
Cash Flow
61
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.90B | 2.77B | 2.51B | 2.36B | 2.29B |
| Gross Profit | 492.05M | 510.71M | 458.31M | 464.44M | 492.51M |
| EBITDA | 304.07M | 223.61M | 84.01M | 206.17M | 283.44M |
| Net Income | 116.95M | 20.51M | -11.22M | 115.79M | 174.15M |
Balance Sheet | |||||
| Total Assets | 1.42B | 1.31B | 1.30B | 1.27B | 1.13B |
| Cash, Cash Equivalents and Short-Term Investments | 213.43M | 251.20M | 185.15M | 139.98M | 81.09M |
| Total Debt | 326.89M | 363.56M | 376.07M | 335.48M | 262.58M |
| Total Liabilities | 907.58M | 853.41M | 816.38M | 758.19M | 729.68M |
| Stockholders Equity | 507.56M | 452.26M | 471.44M | 493.17M | 364.45M |
Cash Flow | |||||
| Free Cash Flow | 143.06M | 187.65M | 156.91M | 141.66M | 180.19M |
| Operating Cash Flow | 235.81M | 223.06M | 206.72M | 205.71M | 231.64M |
| Investing Cash Flow | -96.30M | -34.05M | -73.82M | -79.02M | -124.25M |
| Financing Cash Flow | -177.29M | -122.96M | -87.73M | -67.80M | -167.71M |
Danel Technical Analysis
Positive
46430.00
Price Trends
45526.41
Positive
45928.19
Positive
46216.30
Negative
Market Momentum
-242.17
Negative
55.65
Neutral
54.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:DANE, the sentiment is Positive. The current price of 46430 is above the 20-day moving average (MA) of 44916.43, above the 50-day MA of 45526.41, and above the 200-day MA of 46216.30, indicating a neutral trend. The MACD of -242.17 indicates Negative momentum. The RSI at 55.65 is Neutral, neither overbought nor oversold. The STOCH value of 54.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IL:DANE.
Danel Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ₪1.38B | ― | ― | 1.69% | 9.07% | 38.76% | |
64 Neutral | ₪748.84M | 11.00 | ― | ― | ― | ― | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | ₪2.61B | 23.22 | ― | 2.98% | 5.94% | -52.48% | |
52 Neutral | ₪5.19B | 23.28 | ― | 4.01% | 6.10% | -9.48% | |
44 Neutral | ₪510.87M | 155.92 | ― | 3.05% | 22.79% | ― |
* Consumer Defensive Sector Average
IL:DANE
Danel
46,000.00
8,550.41
22.83%
IL:DIPL
Diplomat Holdi.
4,995.00
1,052.79
26.71%
IL:TTAM
Tiv Taam
1,306.00
650.71
99.30%
IL:WLFD
Willy Food
5,565.00
2,861.00
105.81%
IL:RMLI
Rami Levi
37,270.00
12,098.85
48.07%
IL:NVLG
Novolog
101.30
-45.49
-30.99%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.